Subtype
Pancreatic Mucinous Cystic Neoplasm
CI-CAN-00001354Explore in graph →
Non-malignant8 active trials
Loading cancer entity…
Subtype
CI-CAN-00001354Explore in graph →
Clinical trials
45 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04207944 | The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) | active not recruiting | Phase 2 | 100 | Duke UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06519097 | Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) | active not recruiting | Phase 2 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT03188991 |
| Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms |
| completed |
| Phase 2 |
| 20 |
| NanOlogy, LLCINDUSTRY |
| 1 |
| Jun 14, 2021 |
| clinicaltrials |
| NCT00689715 | Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas(EUS-EP) | unknown | Phase 2 / Phase 3 | 50 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00482625 | Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials